Page last updated: 2024-09-03

gefitinib and raloxifene hydrochloride

gefitinib has been researched along with raloxifene hydrochloride in 2 studies

Compound Research Comparison

Studies (gefitinib)	Trials (gefitinib)	Recent Studies (post-2010) (gefitinib)	Studies (raloxifene hydrochloride)	Trials (raloxifene hydrochloride)	Recent Studies (post-2010) (raloxifene hydrochloride)
5,231	566	2,919	2,818	481	810

Protein Interaction Comparison

Protein	Taxonomy	raloxifene hydrochloride (IC50)
Estrogen receptor	Homo sapiens (human)	0.0053
Gastric inhibitory polypeptide receptor	Homo sapiens (human)	0.0004
Estrogen receptor beta	Homo sapiens (human)	0.1297

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Ariazi, E; Bertucci, A; Grigg, R; Jordan, VC; Lee, ES; Meeke, K; Morris, C; O'Regan, RM; Osipo, C; Sarker, MA	1
Rosengren, RJ; Taurin, S	1

Other Studies

2 other study(ies) available for gefitinib and raloxifene hydrochloride

Article	Year
Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Apr-01, Volume: 12, Issue:7 Pt 1 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Quinazolines; Raloxifene Hydrochloride; RNA, Messenger; Structure-Activity Relationship; Transplantation, Heterologous; Trastuzumab; Xenograft Model Antitumor Assays	2006
Raloxifene potentiates the effect of gefitinib in triple-negative breast cancer cell lines. Medical oncology (Northwood, London, England), 2022, Dec-09, Volume: 40, Issue:1 Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Endothelial Cells; Gefitinib; Humans; Protein Kinase Inhibitors; Quinazolines; Raloxifene Hydrochloride; Triple Negative Breast Neoplasms	2022

Article

Year

Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Apr-01, Volume: 12, Issue:7 Pt 1

Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Quinazolines; Raloxifene Hydrochloride; RNA, Messenger; Structure-Activity Relationship; Transplantation, Heterologous; Trastuzumab; Xenograft Model Antitumor Assays

2006

Raloxifene potentiates the effect of gefitinib in triple-negative breast cancer cell lines.

Medical oncology (Northwood, London, England), 2022, Dec-09, Volume: 40, Issue:1

Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Endothelial Cells; Gefitinib; Humans; Protein Kinase Inhibitors; Quinazolines; Raloxifene Hydrochloride; Triple Negative Breast Neoplasms

2022